BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27170998)

  • 1. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
    Yako YY; Kruger D; Smith M; Brand M
    PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.
    Yako YY; Brand M; Smith M; Kruger D
    Pancreatology; 2017; 17(3):438-444. PubMed ID: 28377069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
    Chung HW; Lim JB
    J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
    Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
    Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble stroma-related biomarkers of pancreatic cancer.
    Resovi A; Bani MR; Porcu L; Anastasia A; Minoli L; Allavena P; Cappello P; Novelli F; Scarpa A; Morandi E; Falanga A; Torri V; Taraboletti G; Belotti D; Giavazzi R
    EMBO Mol Med; 2018 Aug; 10(8):. PubMed ID: 29941541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
    Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
    Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum  JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients.
    Petrusel L; Ilies M; Leucuta D; Rusu I; Seicean A; Iuga C; Seicean R
    Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):107-112. PubMed ID: 34933726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
    Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
    Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
    Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
    Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
    PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma.
    Chung HW; Jang S; Lim JB
    Cancer; 2013 Jan; 119(1):233-44. PubMed ID: 22736451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
    Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
    Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
    Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
    Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.